Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Recursion Pharmaceuticals, Inc. (RXRX) had Receiveable Turnover of 1.44 for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$35.54M |
|
$-108.12M |
|
$14.28M |
|
$21.26M |
|
$143.87M |
|
$-108.33M |
|
$0.23M |
|
$-108.10M |
|
$-108.10M |
|
$-108.12M |
|
$-108.12M |
|
$-108.12M |
|
$-108.12M |
|
$-108.33M |
|
$-88.86M |
|
447.45M |
|
447.45M |
|
$-0.17 |
|
$-0.17 |
|
| Balance Sheet Financials | |
$812.85M |
|
$103.93M |
|
$661.28M |
|
$1.47B |
|
$147.71M |
|
$9.56M |
|
$195.56M |
|
$343.26M |
|
$1.13B |
|
$658.80M |
|
$1.13B |
|
528.18M |
|
| Cash Flow Statement Financials | |
$-371.81M |
|
$-16.87M |
|
$521.53M |
|
$603.02M |
|
$753.92M |
|
$150.90M |
|
$111.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.50 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
59.83% |
|
-304.84% |
|
-304.84% |
|
-- |
|
-304.19% |
|
-304.24% |
|
$-378.28M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
|
Receiveable Turnover |
1.44 |
62.42 |
|
-9.56% |
|
-16.41% |
|
-7.33% |
|
-9.48% |
|
$2.14 |
|
$-0.85 |
|
$-0.83 |
|